RadNet, Inc. (NASDAQ:RDNT) Director Michael L. Md Sherman sold 11,965 shares of RadNet stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $11.02, for a total value of $131,854.30. Following the sale, the director now directly owns 289,992 shares of the company’s stock, valued at approximately $3,195,711.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

RadNet, Inc. (NASDAQ:RDNT) opened at 11.12 on Friday. RadNet, Inc. has a 12 month low of $5.25 and a 12 month high of $11.50. The company’s 50-day moving average price is $9.20 and its 200 day moving average price is $7.32. The stock has a market capitalization of $525.83 million, a PE ratio of 58.55 and a beta of 0.92.

RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. RadNet had a net margin of 1.04% and a return on equity of 19.98%. The company had revenue of $230.00 million during the quarter, compared to analyst estimates of $230.32 million. During the same period last year, the business earned $0.09 earnings per share. RadNet’s revenue was up 5.2% compared to the same quarter last year. On average, analysts forecast that RadNet, Inc. will post $0.30 earnings per share for the current fiscal year.

WARNING: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/insider-selling-radnet-inc-rdnt-director-sells-131854-30-in-stock.html.

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of RadNet by 6.6% in the first quarter. Geode Capital Management LLC now owns 274,192 shares of the medical research company’s stock valued at $1,617,000 after acquiring an additional 16,924 shares during the period. Vanguard Group Inc. boosted its position in shares of RadNet by 2.5% in the first quarter. Vanguard Group Inc. now owns 1,233,623 shares of the medical research company’s stock valued at $7,278,000 after acquiring an additional 30,054 shares during the period. TFS Capital LLC boosted its position in shares of RadNet by 238.0% in the first quarter. TFS Capital LLC now owns 121,948 shares of the medical research company’s stock valued at $719,000 after acquiring an additional 85,872 shares during the period. American International Group Inc. boosted its position in shares of RadNet by 7.0% in the first quarter. American International Group Inc. now owns 22,857 shares of the medical research company’s stock valued at $135,000 after acquiring an additional 1,500 shares during the period. Finally, Cadence Capital Management LLC boosted its position in shares of RadNet by 32.5% in the first quarter. Cadence Capital Management LLC now owns 171,565 shares of the medical research company’s stock valued at $1,012,000 after acquiring an additional 42,107 shares during the period. Institutional investors own 48.81% of the company’s stock.

RDNT has been the subject of a number of research reports. Jefferies Group LLC raised RadNet from a “hold” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $12.00 in a report on Tuesday, August 22nd. BidaskClub upgraded RadNet from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 24th. Finally, TheStreet upgraded RadNet from a “c” rating to a “b-” rating in a research report on Thursday, August 24th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.63.

About RadNet

RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.

Insider Buying and Selling by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.